Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Ipsen

Status and phase

Completed

Phase 3

Conditions

Glabellar Lines

Treatments

Biological: Botulinum toxin type A

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02450526

Y-52-52120-158

Details and patient eligibility

About

The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement in appearance of moderate to severe glabellar lines in Chinese subjects.

Full description

The first treatment cycle will be double blind and subjects will be randomised to receive Dysport, Botox or placebo. After the first treatment cycle, all subjects will receive a maximum of four treatment cycles with Dysport, occurring at intervals of no less than 84 Days (12 weeks) between each treatment cycle, depending upon individual duration of response to Dysport treatment.

Enrollment

520 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of written informed consent
Male or female Chinese subjects who are between 18 to 65 years of age inclusive.
Have moderate or severe wrinkles of vertical glabellar lines (Grade 2 or 3) at maximum frown at baseline (Day 1), as assessed by the subject using SSA.
Have moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at baseline (Day 1), as assessed by the Investigator using ILA.
Be Botulinum Toxin (BTX) naïve or have received their most recent BTX-A treatment more than 1 year prior to screening.
Have a negative pregnancy test
Have an understanding of the study

Exclusion criteria

Any prior surgery affecting corrugator supercilii, prior blepharoplasty or brow lift, dermal resurfacing, or any prior cosmetic procedures or scars within 36 months.
Any prior treatment with permanent fillers in the upper face.
Any prior treatment with nonpermanent dermal fillers in the upper face within the past 3 years and/or skin abrasions/resurfacing, photorejuvenation or skin/vascular laser intervention within the past 12 months.
Any planned facial cosmetic surgery or procedures during the study period.
Lack of capacity to frown.
Facial conditions that could affect safety or efficacy results.
History of facial nerve palsy.
Marked asymmetry; ptosis; excessive dermatochalasis; deep dermal scarring; thick sebaceous skin; photodamage etc.
Presence of any condition that could affect the safety, conduct or outcome of the study.
Any subjects who have any psychiatric illness or are taking antidepressant, anxiolytic or antipsychotic medication.
Pregnant and/or lactating female subjects.
Female subjects of childbearing potential not willing to use contraceptive measures throughout the course of the study.
History of drug or alcohol abuse.
Treatment with an experimental drug or device within 30 days prior to screening for this study and during the conduct of this study.
Requirement for BTX injection to site(s) for disorders other than glabellar lines.
Known allergy or hypersensitivity to BTX.
Any medical condition or laboratory finding from central laboratory results.
The subject is unable and/or unwilling to comply fully with the protocol and the study.
Mental incapacity, unwillingness or language barriers.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

520 participants in 4 patient groups, including a placebo group

AbobotulinumtoxinA

Experimental group

Description:

Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.

Treatment:

Biological: Botulinum toxin type A

OnabotulinumtoxinA

Active Comparator group

Description:

Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.

Treatment:

Biological: Botulinum toxin type A

AbobotulinumtoxinA Placebo

Placebo Comparator group

Description:

Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.